“CLINICAL-PATOGENETIC RATIONALE FOR THE USE OF GLYCOSAMINOGLYCANS IN THE TREATMENT OF PATIENTS WITH GLOMERULONEPHRITIS”. 2023. Art of Medicine 28 (4): 88-93. https://doi.org/10.21802/artm.2023.4.28.88.